Harbor Capital Advisors Inc. raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 99.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 48,063 shares of the biopharmaceutical company's stock after acquiring an additional 23,947 shares during the period. Harbor Capital Advisors Inc. owned 0.06% of Xenon Pharmaceuticals worth $1,892,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Xenon Pharmaceuticals in the first quarter worth $17,941,000. Affinity Asset Advisors LLC raised its position in Xenon Pharmaceuticals by 82.0% in the first quarter. Affinity Asset Advisors LLC now owns 837,387 shares of the biopharmaceutical company's stock worth $36,050,000 after purchasing an additional 377,387 shares in the last quarter. Logos Global Management LP acquired a new position in Xenon Pharmaceuticals in the second quarter worth about $14,621,000. Ikarian Capital LLC increased its holdings in shares of Xenon Pharmaceuticals by 169.6% during the first quarter. Ikarian Capital LLC now owns 107,187 shares of the biopharmaceutical company's stock worth $4,614,000 after buying an additional 261,276 shares in the last quarter. Finally, Artal Group S.A. acquired a new stake in shares of Xenon Pharmaceuticals during the first quarter worth approximately $10,908,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Trading Up 3.9 %
Shares of XENE stock traded up $1.62 on Tuesday, reaching $43.33. The company's stock had a trading volume of 218,098 shares, compared to its average volume of 386,063. The stock's fifty day simple moving average is $40.67 and its 200-day simple moving average is $40.19. The company has a market capitalization of $3.28 billion, a price-to-earnings ratio of -15.81 and a beta of 1.25. Xenon Pharmaceuticals Inc. has a 1 year low of $27.99 and a 1 year high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.05). During the same period last year, the company posted ($0.72) EPS. Equities research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the stock. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Wedbush lowered their price target on shares of Xenon Pharmaceuticals from $50.00 to $49.00 and set an "outperform" rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada reissued an "outperform" rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Needham & Company LLC reduced their target price on shares of Xenon Pharmaceuticals from $62.00 to $60.00 and set a "buy" rating for the company in a report on Monday, August 12th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Xenon Pharmaceuticals in a report on Friday, August 9th. Eleven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $57.45.
Get Our Latest Report on XENE
Xenon Pharmaceuticals Profile
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Read More
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
